Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.
| Class:Id | Summation:9702793 |
|---|---|
| _displayName | Therapeutic agents that block the calcitonin gene-related pe... |
| _timestamp | 2020-10-02 10:45:35 |
| created | [InstanceEdit:9702847] Jassal, Bijay, 2020-10-02 |
| text | Therapeutic agents that block the calcitonin gene-related peptide (CALCA, CGRP) signaling pathway are efficacious for both acute migraine treatment and migraine prevention. Erenumab (AMG 334) is a fully human monoclonal antibody against the CGRP receptor (CALCR) that competes with CALCA binding to human CALCR, inhibiting CALCA-stimulated cAMP production (Shi et al. 2016). In studies of efficacy of erenumab in patients with episodic migraine, it provided sustained efficacy in episodic migraine with good tolerability (Goadsby et al. 2020, Broessner et al. 2020). |
| (summation) | [Reaction:9702818] CALCR binds erenumab [Homo sapiens] |
| [Change default viewing format] | |